Academy of Medical Sciences of I.R. Iran Archives of Iranian Medicine 1029-2977 23 8 2020 08 01 Diabetes Management during the COVID-19 Pandemic: An Iranian Expert Opinion Statement 564 567 10.34172/aim.2020.61 EN Mojtaba Malek https://orcid.org/0000-0002-8277-3351 Farhad Hosseinpanah https://orcid.org/0000-0001-5235-9451 Hamid Reza Aghaei Meybodi https://orcid.org/0000-0003-1754-3450 Seyed Adel Jahed https://orcid.org/0000-0002-0890-0869 Farzad Hadaegh https://orcid.org/0000-0002-0352-8666 Sasan Sharghi https://orcid.org/0000-0003-4461-4429 Alireza Esteghamati https://orcid.org/0000-0001-5114-3982 Mohammad E. Khamseh https://orcid.org/0000-0003-4313-8440 Journal Article 10.34172/aim.2020.61 2020 05 02 2020 06 14 The coronavirus infection is an evolving pandemic with high morbidity and mortality, especially in people with comorbidities. The case fatality rate (CFR) is 9.2% in the presence of diabetes, while it is 1.4% in those without any comorbidity. Diabetes is a prevalent disease globally; hence, healthcare professionals are highly concerned about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic progression. Current evidence does not support higher incidence of coronavirus disease 2019 (COVID-19) in people with diabetes (PWD). However, people with diabetes are considered high risk for developing complications. Optimal metabolic control is a challenging concept, especially in the presence of an acute and severe respiratory viral infection. In this consensus, we considered the challenging issues in management of patients with diabetes during the COVID-19 pandemic. The consensus covers various aspects of outpatient as well as inpatient care based on the current evidence.